Speaker Michael H. Picard, MD provides a historical perspective and critical evaluation of left ventricular ejection fraction (LVEF) as a disease measure in heart failure (HF). The strengths and limitations of LVEF, as well as potential alternative imaging approaches and biomarkers for HF, are discussed. The trajectory of care for patients across the spectrum of LVEF is also highlighted.
Sponsored by Novartis Pharmaceuticals Corporation - Medical Affairs
#LVEF #HF #ACC21
